HDL Cholesterol Reduction during Rosiglitazone and Fenofibrate Treatment in a Type 2 Diabetes Mellitus Patient with Dyslipidemia.
10.3343/kjlm.2010.30.1.17
- Author:
Mijeong IM
1
;
Minki KIM
;
Jin Kyung LEE
;
Yoon Hwan CHANG
;
Dong Young LEE
;
Seok Il HONG
;
Yun Yong LEE
;
Young Jun HONG
Author Information
1. Department of Laboratory Medicine, Korea Cancer Center Hospital, Seoul, Korea. clinchem@kcch.re.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
HDL cholesterol;
Rosiglitazone;
Fenofibrate
- MeSH:
Apolipoprotein A-I/metabolism;
Cholesterol, HDL/*blood;
Diabetes Mellitus, Type 2/complications/*drug therapy;
Dyslipidemias/complications/*drug therapy;
Fenofibrate/*therapeutic use;
Humans;
Hypolipidemic Agents/*therapeutic use;
Male;
Middle Aged;
Thiazolidinediones/*therapeutic use
- From:The Korean Journal of Laboratory Medicine
2010;30(1):17-19
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Thiazolidinediones (TZD), which are widely used as insulin sensitizers, and fibrates, which are lipid-lowering drugs, are used in the treatment of dyslipidemia that commonly accompanies diabetes. Several reports suggest elevated levels of high-density lipoprotein (HDL) cholesterol, but the paradoxical reduction of HDL cholesterol level during single or combined TZD and fibrate therapies has been occasionally reported. Herein, we report a case of paradoxical decrease in HDL cholesterol and apolipoprotein A-1 levels during rosiglitazone and fenofibrate treatment for the first time in Korea. The patient was a 56-yr-old man presenting with type 2 diabetes mellitus and dyslipidemia. His HDL cholesterol and apolipoprotein A-1 levels returned to normal after the cessation of fenofibrate therapy. Since diabetes is an established risk factor of cardiovascular diseases, low HDL cholesterol can be a key cause of concern for patients with diabetes. Therefore, HDL cholesterol level should be determined before and after starting TZD and/or fibrate therapy in diabetic patients.
